CCCC earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -3.14. Updated 2026-07-23.
C4 Therapeutics (CCCC) Research Hub
C4 Therapeutics (CCCC) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.51 USD (+2.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.14, market cap 0.31B. This hub links to the full technical, earnings and options research available for CCCC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.51 USD (+2.03%) |
| 52-week range | 3.355 USD – 5.17 USD |
| Trend regime | Range |
| 14-day RSI | 44.4 (Bearish) |
| Trailing P/E | -3.14 |
| Market cap | 0.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CCCC
Covered Call on CCCC: how it works, illustrative setup around the real 3.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CCCC: how it works, illustrative setup around the real 3.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CCCC: how it works, illustrative setup around the real 3.51 USD price, max profit/loss, breakeven and when to use it. Educational.
CCCC technical analysis: range, last 3.51 USD, RSI 44.4, 52w range 3.355 USD–5.17 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CCCC in?
C4 Therapeutics (CCCC) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CCCC in an uptrend or downtrend?
As of 2026-09-11, CCCC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CCCC's trailing P/E ratio?
CCCC's trailing P/E is -3.14, with a market cap of 0.31B. See the earnings research page for full valuation detail.
When does CCCC next report earnings?
CCCC is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.23 USD.